PEN — Penumbra Inc
—
NYSE ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1321732 ·
Last close
$319.11
Market Cap
$12.58B
52W High
$362.41
52W Low
$276.01
ADV30
373,053
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 390,046,000 | 264,944,000 | 41,039,000 | 34,811,000 | 1,974,723,000 | 205,271,000 | 443,957,000 |
| Mar 2026 | 374,758,000 | 253,411,000 | 38,234,000 | 32,584,000 | 1,898,438,000 | 241,289,000 | 424,626,000 |
| Dec 2025 | 385,385,000 | 262,128,000 | 59,233,000 | 47,343,000 | 1,826,519,000 | 186,897,000 | 398,916,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$277,802,000
Investing CF
$-510,232,000
Financing CF
$16,125,000
CapEx
$-61,896,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$3.97
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$305,086,000
Inventory
$442,650,000
Receivables
$190,407,000
ST Investments
$453,524,000
EBIT TTM
$205,131,000
Pretax Income TTM
$203,832,000
Interest Exp TTM
$1,299,000
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,560,333,952
EBITDA
$209,160,992
Free Cash Flow
$166,086,496
Enterprise Value
$12,106,995,712
Total Cash
$673,612,032
Total Debt
$209,390,000
Shares Out
39,414,385
Trailing EPS
$3.97
Book Value
$40.18
ROE
10.7%
ROA
6.3%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,403,665,000 | 189,249,000 | 177,687,000 | 1,826,519,000 | 398,916,000 | 1,427,603,000 | 238,663,000 |
| Dec 2024 | 1,194,615,000 | 86,224,000 | 14,012,000 | 1,533,181,000 | 382,250,000 | 1,150,931,000 | 168,481,000 |
| Dec 2023 | 1,058,522,000 | 91,766,000 | 90,954,000 | 1,556,305,000 | 377,361,000 | 1,178,944,000 | 97,333,000 |
| Dec 2022 | 847,133,000 | 6,082,000 | -2,002,000 | 1,370,886,000 | 372,028,000 | 998,858,000 | -55,661,000 |
TTM Snapshot
Revenues TTM
$1,504,874,000
NetIncome TTM
$160,589,000
OpCashFlow TTM
—
Assets (Latest)
$1,974,723,000
Forward EPS
$6.10
Max Pain — expiry 2026-12-18
max pain strike: $350.00 · spot: $320.60 · call oi: 974 · put oi: 3,188
Expected Move to 2026-12-18:
±$22.30
(6.96%) —
implied range
$298.30 –
$342.90
· ATM straddle on $320.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SNN | SMITH & NEPHEW PLC | $12.77B | $30.51 | — |
| SNNUF | SMITH & NEPHEW PLC | $12.93B | $15.45 | — |
| BAX | BAXTER INTERNATIONAL INC | $13.33B | $25.76 | — |
| ALGN | ALIGN TECHNOLOGY INC | $11.52B | $163.46 | — |
| GKOS | GLAUKOS Corp | $14.40B | $243.25 | — |
News headlines (Yahoo Finance, 1h cache)
Penumbra (PEN) Stock Faces Q3 Earnings Valuation Scrutiny
2026-10-31 14:13 · Yahoo
Penumbra: Q3 Earnings Snapshot
2026-10-29 20:27 · Yahoo
Penumbra, Inc. Reports Third Quarter 2026 Financial Results
2026-10-29 20:05 · Yahoo
Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
2026-10-20 13:00 · Yahoo
Penumbra (PEN) Clinical Data Puts Its Valuation Back In Focus
2026-10-08 16:20 · Yahoo
New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism
2026-10-06 13:00 · Yahoo
IART vs. PEN: Which Stock Is the Better Value Option?
2026-10-01 14:40 · Yahoo
IART or PEN: Which Is the Better Value Stock Right Now?
2026-09-29 14:40 · Yahoo
S&P revises Boston Scientific outlook to negative on franchise pressures
2026-11-06 22:28 · Yahoo
Boston Scientific Q3 Earnings Call Highlights
2026-10-29 06:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.